Details for New Drug Application (NDA): 077139
✉ Email this page to a colleague
NDA 077139 describes CARBOPLATIN, which is a drug marketed by Cipla Ltd, Fresenius Kabi Usa, Hikma, Hospira, Natco Pharma Usa, Pliva, Sandoz, Watson Labs Teva, Accord Hlthcare, Actavis Totowa, Epic Pharma Llc, Eugia Pharma, Gland Pharma Ltd, Meitheal, Norvium Bioscience, Novast Labs, Pharmachemie Bv, Pliva Lachema, Sun Pharm, Teva Parenteral, Teva Pharms Usa, and Teyro Labs, and is included in thirty-three NDAs. It is available from eleven suppliers. Additional details are available on the CARBOPLATIN profile page.
The generic ingredient in CARBOPLATIN is carboplatin. There are eighteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the carboplatin profile page.
The generic ingredient in CARBOPLATIN is carboplatin. There are eighteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the carboplatin profile page.
Summary for 077139
| Tradename: | CARBOPLATIN |
| Applicant: | Teva Pharms Usa |
| Ingredient: | carboplatin |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 077139
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INTRAVENOUS | Strength | 50MG/5ML (10MG/ML) | ||||
| Approval Date: | Sep 21, 2005 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INTRAVENOUS | Strength | 150MG/15ML (10MG/ML) | ||||
| Approval Date: | Sep 21, 2005 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INTRAVENOUS | Strength | 450MG/45ML (10MG/ML) | ||||
| Approval Date: | Sep 21, 2005 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
